Asking More of Small Molecule KRAS Inhibition: Combination with Immunotherapy & Beyond G12C
Time: 12:15 pm
day: Day Two Track B AM
Details:
• Overall prognosis remains poor for KRAS mutant patients
• Olomorasib is a potent 2nd generation G12C inhibitor with early combination efficacy data suggesting olomorasib may be suited for 1L combinations with standard of care immunotherapy regimens in advanced NSCLC
• Borrowing from the discovery learnings from olomorasib, a highly mutant-selective G12D inhibitor and an isoform selective Pan-KRAS inhibitor are emerging from discovery
